Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and marrow transplant clinical trials network #1102 study rationale, design, and methods

Wael Saber, Jennifer Le-Rademacher, Mikkael Sekeres, Brent Logan, Moira Lewis, Adam Mendizabal, Eric Leifer, Frederick R. Appelbaum, Mary M. Horowitz, Ryotaro Nakamura, Corey S. Cutler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic hematopoietic cell transplantation (alloHCT) to older patients with myelodysplastic syndromes (MDS). However, the relative risks and benefits of alloHCT compared with novel nontransplant therapies continue to be the source of considerable uncertainty. We will perform a prospective biologic assignment trial to compare RIC alloHCT with nontransplant therapies based on donor availability. Primary outcome is 3-year overall survival. Secondary outcomes include leukemia-free survival, quality of life, and cost-effectiveness. Four hundred patients will be enrolled over roughly 3years. Planned subgroup analyses will evaluate key biologic questions, such as the impact of age and response to hypomethylating agents on treatment effects. Findings from this study potentially may set a new standard of care for older MDS patients who are considered candidates for alloHCT.

Original languageEnglish (US)
Pages (from-to)1566-1572
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Cell Transplantation
Patient Care
Bone Marrow
Clinical Trials
Transplants
Survival
Therapeutics
Standard of Care
Uncertainty
Cost-Benefit Analysis
Leukemia
Quality of Life
Tissue Donors

Keywords

  • Biologic assignment
  • MDS
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome : Blood and marrow transplant clinical trials network #1102 study rationale, design, and methods. / Saber, Wael; Le-Rademacher, Jennifer; Sekeres, Mikkael; Logan, Brent; Lewis, Moira; Mendizabal, Adam; Leifer, Eric; Appelbaum, Frederick R.; Horowitz, Mary M.; Nakamura, Ryotaro; Cutler, Corey S.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 10, 01.10.2014, p. 1566-1572.

Research output: Contribution to journalArticle

@article{f52cce82368641feb4ea254ccfc5b7d6,
title = "Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and marrow transplant clinical trials network #1102 study rationale, design, and methods",
abstract = "The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic hematopoietic cell transplantation (alloHCT) to older patients with myelodysplastic syndromes (MDS). However, the relative risks and benefits of alloHCT compared with novel nontransplant therapies continue to be the source of considerable uncertainty. We will perform a prospective biologic assignment trial to compare RIC alloHCT with nontransplant therapies based on donor availability. Primary outcome is 3-year overall survival. Secondary outcomes include leukemia-free survival, quality of life, and cost-effectiveness. Four hundred patients will be enrolled over roughly 3years. Planned subgroup analyses will evaluate key biologic questions, such as the impact of age and response to hypomethylating agents on treatment effects. Findings from this study potentially may set a new standard of care for older MDS patients who are considered candidates for alloHCT.",
keywords = "Biologic assignment, MDS, Transplantation",
author = "Wael Saber and Jennifer Le-Rademacher and Mikkael Sekeres and Brent Logan and Moira Lewis and Adam Mendizabal and Eric Leifer and Appelbaum, {Frederick R.} and Horowitz, {Mary M.} and Ryotaro Nakamura and Cutler, {Corey S.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.bbmt.2014.06.010",
language = "English (US)",
volume = "20",
pages = "1566--1572",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome

T2 - Blood and marrow transplant clinical trials network #1102 study rationale, design, and methods

AU - Saber, Wael

AU - Le-Rademacher, Jennifer

AU - Sekeres, Mikkael

AU - Logan, Brent

AU - Lewis, Moira

AU - Mendizabal, Adam

AU - Leifer, Eric

AU - Appelbaum, Frederick R.

AU - Horowitz, Mary M.

AU - Nakamura, Ryotaro

AU - Cutler, Corey S.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic hematopoietic cell transplantation (alloHCT) to older patients with myelodysplastic syndromes (MDS). However, the relative risks and benefits of alloHCT compared with novel nontransplant therapies continue to be the source of considerable uncertainty. We will perform a prospective biologic assignment trial to compare RIC alloHCT with nontransplant therapies based on donor availability. Primary outcome is 3-year overall survival. Secondary outcomes include leukemia-free survival, quality of life, and cost-effectiveness. Four hundred patients will be enrolled over roughly 3years. Planned subgroup analyses will evaluate key biologic questions, such as the impact of age and response to hypomethylating agents on treatment effects. Findings from this study potentially may set a new standard of care for older MDS patients who are considered candidates for alloHCT.

AB - The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic hematopoietic cell transplantation (alloHCT) to older patients with myelodysplastic syndromes (MDS). However, the relative risks and benefits of alloHCT compared with novel nontransplant therapies continue to be the source of considerable uncertainty. We will perform a prospective biologic assignment trial to compare RIC alloHCT with nontransplant therapies based on donor availability. Primary outcome is 3-year overall survival. Secondary outcomes include leukemia-free survival, quality of life, and cost-effectiveness. Four hundred patients will be enrolled over roughly 3years. Planned subgroup analyses will evaluate key biologic questions, such as the impact of age and response to hypomethylating agents on treatment effects. Findings from this study potentially may set a new standard of care for older MDS patients who are considered candidates for alloHCT.

KW - Biologic assignment

KW - MDS

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84912532203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912532203&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.06.010

DO - 10.1016/j.bbmt.2014.06.010

M3 - Article

C2 - 24972249

AN - SCOPUS:84912532203

VL - 20

SP - 1566

EP - 1572

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -